Multiple Mononeuropathy Secondary to Parvovirus B19 Infection: A Case Series.
Saved in:
| Title: | Multiple Mononeuropathy Secondary to Parvovirus B19 Infection: A Case Series. |
|---|---|
| Authors: | Theuriet, Julian (AUTHOR), Michaud, Maud (AUTHOR), Fargeot, Guillaume (AUTHOR), Labeyrie, Céline (AUTHOR), Grosset, Anaïs (AUTHOR), Bucy, Maude (AUTHOR), Kouton, Ludivine (AUTHOR), Hubben, Florian (AUTHOR), Manel, Véronique (AUTHOR), Cluse, Florent (AUTHOR), Bohic, Adrien (AUTHOR), Rodriguez, Nicolas (AUTHOR), Petiot, Philippe (AUTHOR), Billaud, Geneviève (AUTHOR), Fabry, Vincent (AUTHOR), Cintas, Pascal (AUTHOR), Maisonobe, Thierry (AUTHOR), Viala, Karine (AUTHOR), Debs, Rabab (AUTHOR), Psimaras, Dimitri (AUTHOR) |
| Source: | European Journal of Neurology. Mar2026, Vol. 33 Issue 3, p1-8. 8p. |
| Subjects: | Parvovirus B19, Neurologic manifestations of general diseases, Clinical immunology, Nervous system injuries, Peripheral nerve tumors, Prognosis, Sensory disorders, Immunoregulation |
| Abstract: | Background: Parvovirus B19 (B19V) infection has been associated with neurological complications. Rarely, patients present with multiple mononeuropathy (MM). The present study aimed to better characterize the clinical, electrophysiological, and prognostic features of patients with B19V‐related MM. Methods: This retrospective, observational, multicenter study included patients with B19V‐related MM diagnosed between January 2015 and January 2025 in seven university hospitals in France and Switzerland. Results: Twenty‐one patients were included. Twelve were female (57%). All were immunocompetent. The median age at symptom onset was 40 years [IQR: 31–44]. All patients experienced sensory symptoms, 19 (90%) reported neuropathic pain, nine (43%) developed motor weakness, and seven (33%) had cranial nerve involvement. The most frequently involved nerves were the median (14 patients, 67%), fibular (n = 13; 62%), and ulnar (n = 10; 48%) nerves. B19V IgM antibodies were present in 12/20 patients (60%), and all 21 patients were positive for IgG. B19V DNA was detected in blood by PCR in 20 patients (95%). Nerve biopsy showed necrotizing small‐vessel vasculitis in one patient (17%), perivascular lymphocytic and macrophagic infiltrates in five (83%), and B19V DNA was detected by PCR in all four tested nerves. Most patients received immunomodulatory treatment (n = 19; 90%). MM relapse occurred in four patients (19%). A partial recovery was observed in 17/20 patients (85%), two remained stable (10%), and one achieved complete recovery (5%). Conclusions: B19V infection should be systematically investigated in patients presenting with MM, especially in young individuals (including children) with predominantly sensory symptoms, predominant upper limb nerve involvement, and/or cranial nerve involvement. [ABSTRACT FROM AUTHOR] |
| Copyright of European Journal of Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Background: Parvovirus B19 (B19V) infection has been associated with neurological complications. Rarely, patients present with multiple mononeuropathy (MM). The present study aimed to better characterize the clinical, electrophysiological, and prognostic features of patients with B19V‐related MM. Methods: This retrospective, observational, multicenter study included patients with B19V‐related MM diagnosed between January 2015 and January 2025 in seven university hospitals in France and Switzerland. Results: Twenty‐one patients were included. Twelve were female (57%). All were immunocompetent. The median age at symptom onset was 40 years [IQR: 31–44]. All patients experienced sensory symptoms, 19 (90%) reported neuropathic pain, nine (43%) developed motor weakness, and seven (33%) had cranial nerve involvement. The most frequently involved nerves were the median (14 patients, 67%), fibular (n = 13; 62%), and ulnar (n = 10; 48%) nerves. B19V IgM antibodies were present in 12/20 patients (60%), and all 21 patients were positive for IgG. B19V DNA was detected in blood by PCR in 20 patients (95%). Nerve biopsy showed necrotizing small‐vessel vasculitis in one patient (17%), perivascular lymphocytic and macrophagic infiltrates in five (83%), and B19V DNA was detected by PCR in all four tested nerves. Most patients received immunomodulatory treatment (n = 19; 90%). MM relapse occurred in four patients (19%). A partial recovery was observed in 17/20 patients (85%), two remained stable (10%), and one achieved complete recovery (5%). Conclusions: B19V infection should be systematically investigated in patients presenting with MM, especially in young individuals (including children) with predominantly sensory symptoms, predominant upper limb nerve involvement, and/or cranial nerve involvement. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 13515101 |
| DOI: | 10.1111/ene.70565 |
